Lessons Learned About Clinically Meaningful Benefit from Antiamyloid Trials: Ronald C. Petersen, MD, PhD
The director of the Alzheimer’s Disease Research Center at Mayo Clinic provided perspective on the emergence in antiamyloid therapies, assessing clinically meaningful benefit, and potential changes to trial design in the future. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
"Taking a look at the bigger picture of all these possible proteins operating in concert, if we impact 1 of them, either amyloid or any of the others in isolation, how much of a clinical impact are we likely to have? We’re seeing in trials now that the degree of impact is clinically meaningful, it’s important, but it’s certainly not the whole picture. We need to look at the broader context of these proteins and how they may be interacting together."
Due to complex pathology of Alzheimer disease (AD), trying to understand the true impact of a therapy has been a challenge that many in the field have been tirelessly working to solve. Today, there are hundreds of ongoing trials assessing agents for the disease, all in different stages of development, with the hopes of building out a toolbox of disease-modifying options. After several years of failed approaches and studies, the field finally broke through in 2021 with the approval of aducanumab (Aduhelm; Biogen); however, several continued to question whether these were truly meaningful and beneficial findings.
Questions remain about the time therapies need to show a clinically meaningful effect, as well as whether patients should be treated before symptoms arise. The expansion of biomarkers has allowed for more free discussion about the possibilities of new trial design and inclusion of patients earlier in their disease course; however, there are still issues with access and costs with some of these techniques. Recently, the Alzheimer’s Association
In an interview with NeurologyLive®, lead investigator Ronald C. Petersen, MD, PhD, director of the Alzheimer’s Disease Research Center at
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Current Challenges and New Opportunities Ahead for Women in Neurology
September 15th 2025
- Del-Zota Reverses Duchenne Disease Progression in 1-Year Trial Update
September 15th 2025
- 2025 Women in Neurology Conference: Educating, Mentoring, and Networking
September 15th 2025
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025